CTD Holdings, a biotechnology company that develops cyclodextrin-based products for the treatment of disease, met with a dozen families affected by Niemann-Pick Type C (NPC) at the National Niemann-Pick Disease Foundation’s 23rd Annual Family Support & Medical Conference in Chicago on August 7, 2015.
This special meeting was organized by family representatives, including Chris Hempel who is one of the pioneering advocates for research on cyclodextrins as a treatment for NPC, a rare and serious cholesterol metabolism disease found primarily in children. Chris and her husband Hugh Hempel were the first in the world to use cyclodextrins, provided by CTD, for the treatment of their daughters under an IND protocol and in the care of Dr. Caroline Hastings, a member of CTD’s Scientific Advisory Board and Co-Chair of CTD’s Family and Physicians Listening Circle.
At the meeting Dr. Sharon Hrynkow, a founding member of CTD’s Scientific Advisory Board who is leading the company’s clinical program, presented an overview of both CTD’s NPC treatment product, Trappsol Cyclo, and its International Clinical Program that seeks to gain market approval for Trappsol Cyclo. CTD Executive Chairman N. Scott Fine and CTD Scientific Advisory Board and Listening Circle members Dr. Hastings; Dr. Benny Liu, who conducted seminal studies in a mouse model showing that cyclodextrins were effective in removing cholesterol from the body; and Dr. Camilo Vieira, the first physician to use Trappsol Cyclo to treat NPC patients in Brazil, also participated at the meeting and answered questions from families.
Mr. Fine assured families that CTD is "in it for the long haul" to help them battle NPC and he affirmed the company's dedication to achieving market approval for Trappsol Cyclo. Mr. Fine and Dr. Hrynkow invited families to join CTD’s Family and Physicians Listening Circle as a means to interact with leading scientists and to offer insights as CTD’s clinical trial is developed.
CTD thanks Ms. Nadine Hill, Executive Director of the National Niemann-Pick Disease Foundation for supporting and attending the meeting. In closing, Dr. Hrynkow pledged to provide more information on the clinical trial protocol, noting, "We want to share as much information with the NPC community as soon as we can."